ANGLE’s Parsortix system used in new cancer biology research
Ella Day | June 10, 2025 | News story | Medical Communications, Research and Development | Angle, Oncology, Parsortix system, R&D, biotech, oncology, scientific journals
ANGLE has announced three new peer-reviewed publications demonstrating the use of its Parsortix circulating tumour cell (CTC) harvesting system in studies exploring cancer biology and therapeutic targets. The research, led by academic groups in Germany, Ireland and the US, supports the system’s growing role in advancing oncology R&D.
In one study, published in Journal of Experimental & Clinical Cancer Research, Klaus Pantel’s team at University Medical Center Hamburg-Eppendorf, Germany, used Parsortix to detect both cancerous and healthy cell release into the bloodstream during prostatectomy surgery. The findings raise questions about the risks of intraoperative tumour dissemination.
Meanwhile, researchers at Trinity College Dublin, Ireland, writing in the European Journal of Surgical Oncology, applied the system to rare epithelial ovarian carcinomas. Their work revealed higher CTC yields from local tumour veins compared to peripheral veins, including in early-stage patients – suggesting early systemic spread may occur sooner than expected.
A third paper from the Cleveland Clinic, US, published in Cancers, explored biomechanical cell changes associated with metastasis in breast cancer. Using RNA-sequenced CTCs isolated through Parsortix, the study linked increasing ‘mechanical conditioning scores’ with metastatic progression, potentially informing future anti-fibrotic drug therapeutics.
“We are proud to see ANGLE’s technology increasingly being used to make novel discoveries into the biology of cancer, which may eventually result in new treatment strategies,” said Karen Miller, ANGLE’s chief scientific officer.
Ella Day
10/6/25
Related Content
Cellbyte raises $2.75m to fund pharma drug launch platform
Cellbyte has announced that it has raised $2.75m in seed funding for the streamlining of …
Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …
Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …
